Lateral lymph node dissection for lower rectal cancer.

Area of Science:

• Surgical Oncology
• Gastrointestinal Oncology
• Rectal Cancer Treatment

Background:

• Lower rectal cancer treatment involves complex surgical decisions.
• Lateral lymph node metastasis is a critical factor in rectal cancer prognosis.
• The role of lateral lymph node dissection (LLD) in improving patient outcomes requires further investigation.

Purpose of the Study:

• To evaluate the impact of lateral lymph node dissection (LLD) on survival and recurrence in lower rectal cancer patients.
• To identify prognostic factors influencing outcomes in lower rectal cancer.
• To assess the benefit of LLD in patients with lateral lymph node metastasis.

Main Methods:

• Retrospective review of 169 lower rectal cancer patients (T2 or higher) undergoing curative resection from 1990-2000.
• Comparison of outcomes between 143 patients who underwent LLD and 26 patients who did not.
• Multivariate regression analysis to identify significant prognostic factors.

Main Results:

• LLD was identified as a significant prognostic factor for overall and disease-free survival.
• No significant difference in disease-free survival was observed between LLD and non-LLD groups for Stages I-III disease.
• Local recurrence rates were similar (17.5% with LLD vs. 23.1% without LLD), but LLD benefited patients with lateral lymph node metastasis.

Conclusions:

• LLD can significantly improve outcomes for selected lower rectal cancer patients at high risk for lateral lymph node metastasis.
• LLD may be particularly beneficial for patients with confirmed lateral lymph node metastasis.
• A randomized controlled trial is warranted to definitively establish the role of LLD in rectal cancer treatment.